Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Trejo Becerril, Catalina ^a   Oñate Ocaña, Luis F ^b   Taja Chayeb, Lucía ^a   Vanoye Carlo, América ^a   Cetina, Lucely ^b   Duenas Gonzalez, Alfonso ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NUCLEOSOME; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PROGNOSIS; RADICAL HYSTERECTOMY; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; UTERINE CERVIX CANCER; ADJUVANT CHEMOTHERAPY; ADOLESCENT; BLOOD; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; HYSTERECTOMY; KAPLAN MEIER METHOD; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYSTERECTOMY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEOSOMES; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 26844548732     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-65     Document Type: Article

References (37)

1. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colo rectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1865-1878.
2. Bassetto MA, Franceschi T, Lenotti M, Parise G, Pancheri F, Sabbioni R, Zaninelli M, Cetto GL: AFP and HCG in germ cell tumors. Int J Biol Markers 1994, 9:29-32.
3. Villunger A, Strasser A: Does "death receptor" signaling playa role in tumorigenesis and cancer therapy? Oncol Res 1998, 10:541-550.
4. Martin SI, Green DR: Apoptosis as a goal of cancer therapy. Curr Opin Oncol 1994, 6:616-621.
5. Anker P, Mulcahy H, Chen XQ, Stroun M: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999, 18:65-73.
6. Leon SA, Shapiro B, Sklaroff DM, Yaros DJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
7. Trejo-Becerril C, Rivera L, Chanona J, Segura B, Perez E, Lopez-Graniel C, Hinojosa-Garcia L, Duenas-Gonzalez A: Correlation of tumor growth index with early treatment response in cervical carcinoma. J Exp Clin Cancer Res 2002, 21:57-63.
8. Holdenrieder S, Stieber P, Forg T, Kuhl M, Schulz L, Busch M, Schalhorn A, Seidel D: Apoptosis in serum of patients with solid tumours. Anticancer Res 1999, 19:2721-2724.
9. Trejo-Becerril C, Perez-Cardenas E, Trevino-Cuevas H, Taja-Chayeb L, Garcia-Lopez P, Segura-Pacheco B, Chavez-Blanco A, Lizano-Soberon M, Gonzalez-Fierro A, Mariscal I, Wegman-Ostrosky T, Duenas-Gonzalez A: Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int J Cancer 2003, 104:663-668.
10. Holdenrieder S, Stieber P, Bodenmuller H, Busch M, Fertig G, Furst H, Schalhorn A, Schmeller N, Untch M, Seidel D: Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer (Pred Oncol) 2001, 95:114-120.
11. Kuroi K, Tanaka C, Toi M: Clinical significance of plasma nucleosome levels in cancer patients. Int J Oncol 2001, 19:143-148.
12. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy alter radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000, 18:1606-1613.
13. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ: A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage m carcinoma of the cervix alter radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 1999, 73:177-183.
14. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
15. Mantel N: Evaluation of survival data and the two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
16. Cox DR: Regression model and life tables. J R Stat Assoc 1972, 34:187-220.
17. Searle J, Lawson TA, Abbott PJ, Harmon B, Kerr JFR: An electron-microscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol 1975, 116:129-138.
18. Schmitt CA, Lowe SW: Apoptosis and therapy. J Pathol 1999, 187:127-137.
19. Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuchiya A: Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res 1998, 18:1989-1998.
20. Kato T, Kameoka S, Kimura T, Tanaka S, Nishikawa T, Kobayashi M: p53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer. Anticancer Res 2002, 22:1105-1112.
21. Berker B, Dunder I, Ensari A, Cengiz SD, Simsek E: Prognostic significance of apoptotic index and bcl-2 and p53 expression in epithelial ovarian carcinoma. Eur J Gynecol Oncol 2002, 23:505-510.
22. Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A, Mazzone C, Panetta P, Suppo G, Masi M, Amadori S: Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003, 101:2125-2131.
23. Richter EN, Oevermann K, Buentig N, Storkel S, Dallmann I, Atzpodien J: Primary apoptosis as a prognostic index for the classification of metastatic renal cell carcinoma. J Urol 2002, 168:460-464.
24. Ferreira CG, van der Valk P, Span SW, Ludwig I, Smit EF, Kruyt FA, Pinedo HM, van Tinteren H, Giaccone G: Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 2001, 7:2468-2474.
25. Shibata H, Matsubara O: Apoptosis as an independent prognostic indicator in squamous cell carcinoma of the esophagus. Pathol Int 2001, 51:498-503.
26. Stearns V, Singh B, Tsangaris T, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF: A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003, 9:124-133.
27. Parton M, Krajewski S, Smith I, Krajewska M, Archer C, Naito M, Ahern R, Reed J, Dowsett M: Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res 2002, 8:2100-2108.
28. Holdenrieder S, Stieber P, Bodenmuller H, Busch M, Von Pawel J, Schalhorn A, Nagel D, Seidel D: Circulating nucleosomes in serum. Ann N Y Acad Sci 2001, 945:93-102.
29. Meyn RE, Stephens LC, Hunter NR, Milas L: Kinetics of cisplatin-induced apoptosis in murine mammary and ovarian adenocarcinomas. Int J Cancer 1995, 60:725-729.
30. Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC, Peters LJ: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother PharmacoI 1995, 35:297-303.
31. Milas L, Stephens LC, Meyn RE: Relation of apoptosis to cancer therapy. In Vivo 1994, 8:665-673.
32. Holdenrieder S, Stieber P, van Pawel J, Raith H, Nagel D, Feldmann K, Seidel D: Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004, 10:5981-5987.
33. Miyauchi K, Ogawa M, Shibata T, Matsuda K, Mori T, Ito K, Minamiura N, Yamamoto T: Development of a radioimmunoassay for human deoxyribonuclease I. Clin Chim Acta 1986, 154:115-123.
34. Burlingame RW, Volzer MA, Harris J, Du Clos TW: The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. J Immunol 1996, 156:4783-4788.
35. Gauthier VI, Tyler LN, Mannik M: Blood clearance kinetics and liver uptake of mononucleosomes in mice. J Immunol 1996, 156:1151-1156.
36. Odaka C, Mizuochi T: Role of macrophage lysosomal enzymes in the degradation of nucleosomes of apoptotic cells. J Immunol 1999, 163:5346-5352.
37. Le Lann AD, Foumie GI, Boissier L, Toutain PL, Benoist H: In vitro inhibition of natural- killer-mediated lysis by chromatin fragments. Cancer Immunol Immunother 1994, 39:185-192.